Skip to main content
Acta Crystallographica Section F: Structural Biology and Crystallization Communications logoLink to Acta Crystallographica Section F: Structural Biology and Crystallization Communications
. 2010 Mar 31;66(Pt 4):460–462. doi: 10.1107/S1744309110007050

Crystallization and preliminary X-ray study of the d-­altritol oligonucleotide GTGTACAC

Margriet Ovaere a, Arthur Van Aerschot b, Mikhail Abramov b, Piet Herdewijn b, Luc Van Meervelt a,*
PMCID: PMC2852344  PMID: 20383022

The self-complementary octamer sequence GTGTACAC of the fully modified altritol nucleic acid has been crystallized. Diffraction data have been collected and processed to 3.0 Å resolution.

Keywords: altritol nucleic acids, sugar modification, siRNA

Abstract

In altritol nucleic acids (ANAs), the natural five-membered ribose ring of RNA is replaced by the six-membered d-altritol ring. ANAs are good candidates to act as siRNAs in the RNA-interference pathway. Crystals of the fully modified altritol self-complementary octamer GTGTACAC were grown by the hanging-drop vapour-diffusion technique at 289 K. Diffraction data were recorded on SLS beamline X06DA and processed to 3.0 Å resolution. The crystals belonged to the hexagonal space group P6122 or P6522, with unit-cell parameters a = 25.05, c = 117.58 Å.

1. Introduction

The method of choice nowadays for control of gene expression involves the use of the natural RNAi mechanism, a process in which post-transcriptional gene silencing is obtained (Meister & Tuschl, 2004). Unlike the antisense strategy, in which a single-stranded oligonucleotide with either DNA-like or RNA-like conformational preferences can be used to hybridize with the target mRNA, dsRNA molecules of defined length (or dsRNA mimics, both called small interfering RNAs or siRNAs) are mandatory for loading the RNA-induced silencing complex (RISC). The latter is an enzymatic ensemble that is responsible for breakdown of the target mRNA, following unwinding of the dsRNA and selection and positioning of the correctly remaining antisense strand, allowing hybridization with its target. Hence, exogeneously applied siRNA duplexes can be used for gene silencing, but their enzymatic stability should be improved by chemical modifications in order to increase their lifetime and bio­availability (Dorsett & Tuschl, 2004).

Many different chemical modifications have therefore been studied and much attention has been devoted to locked nucleic acids (LNAs; Elmén et al., 2005; Puri et al., 2008). However, the incorporation of altritol nucleic acid (ANA) monomers (Fig. 1 a) at specific positions has not only been able to augment the intrinsic activity of siRNA molecules, but more important also dramatically increased the persistence of the expected gene-silencing effects (Fisher et al., 2007, 2009). A large-scale screen with chemically modified siRNAs con­firmed the high activity, high stability and low toxicity of the ANAs (Bramsen et al., 2009). Likewise, some other nucleoside analogues with a six-membered ring substituting for the ribofuranose sugar [as in anhydrohexitol (HNA; Fig. 1 b) and cyclohexenyl nucleic acids (CeNAs; Figs. 1 d and 1 e)] have been reported to be endowed with strong siRNA properties (Fisher et al., 2009; Nauwelaerts et al., 2007).

Figure 1.

Figure 1

Comparison of the different monomeric structures of (a) ANA and (b) HNA, both with their base moiety typically oriented axial, (c) DNA in its preferred C2′-endo conformation and (d) left-handed and (e) right-handed CeNA residues, both in their preferred 3 H 2 half-chair conformation mimicking the C3′-endo conformation of ribose nucleosides.

While the RNA-like conformation of ANA modifications has been documented previously (Allart, Khan et al., 1999), the structure of a fully modified duplex has not yet been determined. However, crystal structures of GTGTACAC sequences of HNA (Declercq et al., 2002), CeNA (left-handed structure; Robeyns et al., 2008) and DNA (Jain et al., 1989, 1991; Thota et al., 1993) are already available (Table 1). Solution structures of a CeNA–RNA (Nauwelaerts et al., 2007) and an ANA–RNA duplex (Froeyen et al., 2000) are also available. A complete comparison between the structures of the different modifications therefore becomes possible.

Table 1. Overview of the crystal structures with sequence GTGTACAC available in the Nucleic Acid Database (NDB; Berman et al., 1992) with their corresponding space groups.

NDB code Nucleic acid type Space group
ADH034, ADH038, ADH039 DNA P6122
ADH014§ DNA P43212
HD0001 HNA P3212
HD0002 HNA P6222
UD0068†† CeNA R32

Jain et al. (1991).

Thota et al. (1993).

§

Jain et al. (1989).

Declercq et al. (2002).

††

Robeyns et al. (2008).

2. Methods

2.1. Synthesis and purification

The altritol nucleic acid octamer GTGTACAC was assembled on a solid support using traditional phosphoramidite chemistry as reported previously (Allart, Khan et al., 1999). The phosphoramidite building blocks made use of the benzoyl protecting group for the hydroxyl moiety at the 3′-position of the altritol modifications (Allart, Busson et al., 1999). To isolate the required material, several 1 µmol scale runs were deprotected and purified by ion-exchange chromatography on a Mono Q column using a denaturing NaClO4 gradient in the presence of 15% CH3CN pH 7.4, followed by desalting on a Biogel P2 column. In view of the lower yielding true universal supports and to avoid special synthesis of altritol-functionalized solid supports, a ‘universal’ 3′-end phosphate-generating support was used (Guzaev et al., 1995). Homemade DMTr-sulfonyl-diethanol-LCAA-CPG (80 µmol g−1) was thus prepared, in this case generating a 4′-­phosphate terminus on the fully modified altritol analogue.

2.2. Crystallization

Screening for crystallization conditions was carried out by the hanging-drop vapour-diffusion method at 289 K using the 24-matrix screen for nucleic acid fragments (Berger et al., 1996). 2 µl drops were prepared by mixing 1 µl screen with 1 µl 1.5 mM oligonucleotide and were equilibrated against 500 µl 35% MPD solution. After 2 d, crystals were formed in the condition 40 mM cacodylate pH 7, 12 mM spermine tetrachloride, 40 mM LiCl, 20 mM MgCl2, 80 mM SrCl2 with 10%(v/v) MPD as precipitant. The crystals exhibited a thin plate-like shape with a length of up to 0.9 mm (Fig. 2). The crystals were flash-cooled in liquid nitrogen at 100 K for storage and shipping to the synchrotron facility. No additional cryoprotectant was applied.

Figure 2.

Figure 2

Typical crystals of the ANA self-complementary octamer GTGTACAC.

2.3. Data collection and processing

X-ray diffraction data were recorded at 100 K from a crystal with dimensions 0.22 × 0.06 × 0.01 mm on the Swiss Light Source (SLS, Paul Scherrer Institut, Villigen, Switzerland) X06DA (PXIII) beamline with a sub-100 × 100 µm focused beam at the sample position. Using a MAR225 mosaic CCD detector, a total of 180 frames with a ϕ increment of 1.0° were collected to 2.7 Å resolution at a wavelength of 1.0 Å. The diffraction data were processed using MOSFLM (Leslie, 1992) and scaled using the program SCALA (Evans, 2006) to a 3.0 Å cutoff in order to obtain a reasonable R merge in the outer resolution shell. The latter was used as part of the CCP4 suite (Collaborative Computational Project, Number 4, 1994). At a slightly higher resolution of 2.9 Å the R merge for the outer shell increases to 60% and the I/σ(I) drops to 1.3.

Data-collection statistics are listed in Table 2.

Table 2. Data-collection statistics for the ANA sequence GTGTACAC.

Values in parentheses are for the outermost shell.

X-ray source X06DA (PXIII), SLS
Wavelength (Å) 1.0000
Resolution range (Å) 39.19–3.00 (3.16–3.00)
Space group P6122 or P6522
Unit-cell parameters (Å) a = b = 25.05, c = 117.58
No. of reflections used 9196
No. of unique reflections 579 (88)
Rmerge (%) 3.7 (35.1)
Mean I/σ(I) 39.1 (8.4)
Completeness (%) 99.1 (99.7)
Multiplicity 15.9 (16.3)

3. Results and discussion

Crystals of an altritol-modified oligonucleotide were grown for the first time. The crystals of the ANA sequence GTGTACAC have a hexagonal unit cell with parameters a = b = 25.05, c = 117.58 Å. The diffraction-pattern symmetry belongs to the 622 crystal class. Systematic absence analysis indicated the presence of a 61 or 65 screw axis, resulting in space group P6122 or P6522, respectively. Assignment of the final space group will be made during structure solution.

Based on calculation of the Matthews coefficient, the asymmetric unit cannot contain a full duplex. Estimation of the Matthews co­efficient for half a duplex amounts to 1.97 Å3 Da−1, giving a solvent fraction of 57.8%. The full helix is then generated by a crystallo­graphic twofold axis.

The volume per base pair (bp), assuming 4 bp in the asymmetric unit, is about 1331 Å3. While this value lies within the observed volume range of both A-type DNA (1299–1836 Å3) and B-type DNA (1175–1462 Å3) (Heinemann, 1991), the ANA sequence GTGT­ACAC is likely to crystallize in the A-type family, since both DNA, HNA and CeNA octamers of the same sequence are known to form A-type helices (Table 1). Nevertheless, the potential formation of a B-type helix cannot be excluded.

With the availability of crystallographic models, structure determination was performed by molecular replacement with the program Phaser (McCoy et al., 2007) using all of the models listed in Table 1. Since the asymmetric unit contains only half of the biological unit, the input models were truncated to half a duplex rather than a single strand to avoid the influence of a different helical curvature between the structures. An adequate solution was found in space group P6522 with a four-base-pair model of the HNA structure HD0001. In this solution the other four base pairs are generated by a twofold crystallographic axis. However, refinement using the REFMAC program (Murshudov et al., 1997) did not converge during successive cycles. Plausible causes are flipped-out or disordered bases, the presence of spermine in the crystal structure, which could influence the packing (Jain et al., 1989), or other unresolved features. Structure solution by molecular replacement with A-type and B-type models is still ongoing. In a further attempt to solve the structure, SAD phasing on P atoms as well as on the possibly abundant Mg and Sr atoms will be explored.

Acknowledgments

We are indebted to Guy Schepers for the synthesis and purification of the altritol octamer and thank the staff of Swiss Light Source beamline X06DA in Villigen for help with the synchrotron experiments.

References

  1. Allart, B., Busson, R., Rozenski, J., Van Aerschot, A. & Herdewijn, P. (1999). Tetrahedron, 55, 6527–6546.
  2. Allart, B., Khan, K., Rosemeyer, H., Schepers, G., Hendrix, C., Rothenbacher, K., Seela, F., Van Aerschot, A. & Herdewijn, P. (1999). Chem. Eur. J.5, 2424–2431.
  3. Berger, I., Kang, C., Sinha, N., Wolters, M. & Rich, A. (1996). Acta Cryst. D52, 465–468. [DOI] [PubMed]
  4. Berman, H. M., Olson, W. K., Beveridge, D. L., Westbrook, J., Gelbin, A., Demeny, T., Hsieh, S.-H., Srinivasan, A. R. & Schneider, B. (1992). Biophys. J. 63, 751–759. [DOI] [PMC free article] [PubMed]
  5. Bramsen, J. B. et al. (2009). Nucleic Acids Res.37, 2867–2881. [DOI] [PMC free article] [PubMed]
  6. Collaborative Computational Project, Number 4 (1994). Acta Cryst. D50, 760–763.
  7. Declercq, R., Van Aerschot, A., Read, R. J., Herdewijn, P. & Van Meervelt, L. (2002). J. Am. Chem. Soc.124, 928–933. [DOI] [PubMed]
  8. Dorsett, Y. & Tuschl, T. (2004). Nature Rev. Drug Discov.3, 318–329. [DOI] [PubMed]
  9. Elmén, J., Thonberg, H., Ljungberg, K., Frieden, M., Westergaard, M., Xu, Y., Wahren, B., Liang, Z., Ørum, H., Koch, T. & Wahlestedt, C. (2005). Nucleic Acids Res.33, 439–447. [DOI] [PMC free article] [PubMed]
  10. Evans, P. (2006). Acta Cryst. D62, 72–82. [DOI] [PubMed]
  11. Fisher, M., Abramov, M., Van Aerschot, A., Rozenski, J., Dixit, V., Juliano, R. L. & Herdewijn, P. (2009). Eur. J. Pharmacol.606, 38–44. [DOI] [PMC free article] [PubMed]
  12. Fisher, M., Abramov, M., Van Aerschot, A., Xu, D., Juliano, R. L. & Herdewijn, P. (2007). Nucleic Acids Res.35, 1064–1074. [DOI] [PMC free article] [PubMed]
  13. Froeyen, M., Wroblowski, B., Esnouf, R., De Winter, H., Allart, B., Lescrinier, E. & Herdewijn, P. (2000). Helv. Chim. Acta, 83, 2153–2182.
  14. Guzaev, A., Salo, H., Azhayev, A. & Lonnberg, H. (1995). Tetrahedron, 51, 9375–9384.
  15. Heinemann, U. (1991). J. Biomol. Struct. Dyn.8, 801–811. [DOI] [PubMed]
  16. Jain, S., Zon, G. & Sundaralingam, M. (1989). Biochemistry, 28, 2360–2364. [DOI] [PubMed]
  17. Jain, S., Zon, G. & Sundaralingam, M. (1991). Biochemistry, 30, 3567–3576. [DOI] [PubMed]
  18. Leslie, A. G. W. (1992). Jnt CCP4/ESF–EACBM Newsl. Protein Crystallogr.26
  19. McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C. & Read, R. J. (2007). J. Appl. Cryst.40, 658–674. [DOI] [PMC free article] [PubMed]
  20. Meister, G. & Tuschl, T. (2004). Nature (London), 431, 343–349. [DOI] [PubMed]
  21. Murshudov, G. N., Vagin, A. A. & Dodson, E. J. (1997). Acta Cryst. D53, 240–255. [DOI] [PubMed]
  22. Nauwelaerts, K., Fisher, M., Froeyen, M., Lescrinier, E., Van Aerschot, A., Xu, D., Kang, H., DeLong, R. L., Juliano, R. & Herdewijn, P. (2007). J. Am. Chem. Soc.129, 9340–9348. [DOI] [PubMed]
  23. Puri, N., Wang, X., Varma, R., Burnett, C., Beauchamp, L., Batten, D. M., Young, M., Sule, V., Latham, K., Sendera, T., Echeverri, C., Sachse, C. & Magdaleno, S. (2008). Nucleic Acids Symp. Ser.52, 25–26. [DOI] [PubMed]
  24. Robeyns, K., Herdewijn, P. & Van Meervelt, L. (2008). J. Am. Chem. Soc.130, 1979–1984. [DOI] [PubMed]
  25. Thota, N., Li, X. H., Bingman, C. & Sundaralingam, M. (1993). Acta Cryst. D49, 282–291. [DOI] [PubMed]

Articles from Acta Crystallographica Section F: Structural Biology and Crystallization Communications are provided here courtesy of International Union of Crystallography

RESOURCES